Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer.
TY - JOUR. T1 - Activation of recombinant human protein C. AU - Lee, Timothy K.. AU - Bangalore, Neelesh. AU - Velander, William. AU - Drohan, William N.. AU - Lubon, Henryk. PY - 1996/5/1. Y1 - 1996/5/1. N2 - We have produced recombinant human Protein C (rHPC) in the milk of transgenic swine. After purification, we have analyzed the interaction of the zymogen with Protac, thrombin/thrombomodulin and thrombin alone. The amidolytic and anticoagulant activities of rAPC after Protac activation were ~80% those of its human plasma counterpart. Upon the excision of the activation peptide by thrombin/thrombomodulin complex, both the natural and recombinant activation products had similar enzymatic and biological activities. This. observation can be attributed to the difference in the mechanism of action between the two activators and structural differences between HPC and rHPC.. AB - We have produced recombinant human Protein C (rHPC) in the milk of transgenic swine. After purification, we have ...
JAK2 [V617F] Recombinant Human Protein, JH1 and JH2 Domains 100μg JAK2 [V617F] Recombinant Human Protein, JH1 and JH2 Domains Proteins J
Sino Biological™ CD22 Recombinant Human Protein, His Tag 5 x 5ug Sino Biological™ CD22 Recombinant Human Protein, His Tag Proteins C
Sino Biological™ PPARG Recombinant Human Protein, N-His.GST tag 50μg Sino Biological™ PPARG Recombinant Human Protein, N-His.GST tag Proteins P
GRN Recombinant Human Protein, His Tag, Invitrogen™ Sino Biological™ 5ug GRN Recombinant Human Protein, His Tag, Invitrogen™ Sino Biological™...
MICB Recombinant Human Protein, His Tag, Invitrogen™ Sino Biological™ 5 x 50ug MICB Recombinant Human Protein, His Tag, Invitrogen™ Sino...
Shop a large selection of Proteins F products and learn more about FRAP1 (mTOR) Recombinant Human Protein 10μg FRAP1 (mTOR) Recombinant Human Protein 10μg.
Shop a large selection of Proteins A-Z products and learn more about VEGFC Recombinant Human Protein, His Tag, Invitrogen™ Sino Biological™ 5 x 50ug VEGFC Recombinant
Shop a large selection of Proteins S products and learn more about Invitrogen™ STK17B (DRAK2) Recombinant Human Protein 100μg Invitrogen™ STK17B (DRAK2)
The Global Recombinant Protein Market is anticipated to grow at a CAGR of 11.2% during the forecast period. Recombinant proteins are used in designing new treatments for serious chronic disorders such as cancer and other rare diseases. A special technique known as recombinant DNA (rDNA) technology is used for recombinant protein production. Recombinant proteins are categorized into hormones, growth factor, cytokines, plasma protein factor, recombinant metabolic enzymes, and others, depending on the type of protein.. Recombinant technology is the mechanism involved in the production of industrial recombinant proteins. Industrial recombinant proteins and their derivatives have various applications in industries such as food, pesticides, pharmaceuticals, veterinary, agriculture, and detergents. Due to this, the industrial recombinant protein market is gaining a lot of attention worldwide. As a result, the producers of industrial recombinant protein have found great market opportunities.. Countries ...
Recombinant Human Protein SCO1 Homolog Mitochondrial is produced by our E.coli expression system and the target gene encoding Gly132-Ser300 is expressed with a GST tag at the N-terminus. Bon Opus Cat. #C259
Aldehyde Dehydrogenase 1 family, member A3 (ALDH1A3), recombinant human protein is supplied as a lyophilized powder. In general, recombinant proteins can be used as protein stucture analysis and in cell biology research applications.
This AMPK (A1/B2/G2) recombinant human protein (full length) was expressed in insect cells. AMPK (A1/B2/G2) serine/threonine kinase or AMP-activated protein kinase (AMPK) exhibits a key role as a master regulator of cellular energy homeostasis. AMPK exists as a heterotrimeric complex composed of a c
TY - JOUR. T1 - Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1. AU - Schmitt, David A.. AU - Sasaki, Hidetaka. AU - Pollard, Richard B.. AU - Suzuki, Fujio. PY - 1992/10/1. Y1 - 1992/10/1. N2 - The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice ...
TY - JOUR. T1 - Antiviral effects of recombinant human tumor necrosis factor-alpha in combination with natural interferon-beta in mice infected with herpes simplex virus type 1. AU - Schmitt, David A.. AU - Sasaki, Hidetaka. AU - Pollard, Richard B. AU - Suzuki, Fujio. PY - 1992/10/1. Y1 - 1992/10/1. N2 - The protective effects of combination therapy utilizing recombinant human TNF-alpha (rTNF-α) and natural murine interferon-beta (IFN-β) in mice infected with herpes simplex virus type 1 (HSV-1) was investigated. Mice treated with rTNF-α alone at all of the doses tested (a single i.v. administration, 2.3-2,300 μg/kg; multiple i.p. administrations 0.4-250 μg/kg) as well as mice that received IFN-β alone at doses of 16 × 104 U/kg or less resulted in a 0% survival rate. Combination therapy consisting of a single administration of rTNF- α (230 and 23 μg/kg) and multiple administrations of IFN-β (4 × 104 U/kg) resulted in a 40% and 60% survival rate. Multiple treatments of infected mice ...
Background: The tumor necrosis factor alpha (TNFα) is a cytokine that produced principally by monocyte/macrophages and T lymphocytes, respectively. TNFα is recognized as the primary mediator of immunity in inflammation reaction. One important application of Tumor Necrosis Factor Receptor 2 (TNFR2) is for the treatment of autoimmune diseases like rheumatoid arthritis (RA). Objectives: The aim of this study is to examine the therapeutic trace of the recombinant humanTNFR2 on collagen-induced arthritis (CIA) in mice. Materials and Methods: CIA was created in 20 mice by immunization with bovine type II collagen (CII). After the mice were boosted on day 21, they were injected with the recombinant protein in test group (1 mg.kg-1) and assessed edema in paws and knee joints after two weeks. The quantities of inflammatory cytokines such as TNF-α, interleukin-1 beta (IL-β1), interleukin-6 (IL-6), and interleukin-10(IL-10) in serum were evaluated through enzyme-linked immunosorbent assay (ELISA) kit. In
TY - JOUR. T1 - Nutritional parameters observed during 28-day infusion of recombinant human tumor necrosis factor-α. AU - Hardin, T. C.. AU - Koeller, J. M.. AU - Kuhn, J. G.. AU - Roodman, G. D.. AU - Von Hoff, D. D.. PY - 1993/1/1. Y1 - 1993/1/1. N2 - In conjunction with a Phase I investigation of the antineoplastic activity of recombinant human tumor necrosis factor-α (TNF-α), administered as a 28- day continuous infusion, selected nutritional parameters were evaluated to identify any effect that might be attributed to the TNF infusion. Seven clinically stable men with a variety of tumor types were studied. None had clinical or laboratory evidence of significant malnutrition before entry into the study. Five patients received 10 μg of recombinant human TNF-α per square meter per day and two patients received 25 μg/m2 per day. Indirect calorimetry assessment of resting energy expenditure, body weight, serum TNF concentration, and laboratory analysis of common nutritional markers ...
A neurotrophic factor that promotes the survival of various neuronal cell types and may play an important role in the injury response in the nervous system. Recombinant Human Epidermal Growth Factor produced in E.Coli is a single, non-glycosylated, polype
In the treatment of renal cell carcinoma both complete (CRs) and partial remissions (PRs) have been obtained using recombinant (r) interferon alpha (IFN-alpha), with response rates ranging from 0 to 31% (mean 16%). rIFN-gamma is a potent immunostimulating agent, but the clinical experience of its use is limited and results are conflicting. In a phase II study with the combination of rIFN-alpha(2c) (Boehringer Ingelheim) and rIFN-gamma (Genentech, supplied by Boehringer Ingelheim) in 31 eligible patients, a response rate of 25% was recorded. Based on this observation a randomised phase III study was initiated to investigate the possible advantage of the addition rIFN-gamma to rIFN-alpha(2c) treatment. Treatment consisted of rIFN-alpha(2c) 30 pg m(-2) = 10 x 10(6) IU m(-2) s.c. twice weekly in arm A and the same dose of rIFN-alpha combined with rIFN-gamma 100 mu g m(-2) = 2 x 10(6) IU m(-2) in arm B. Eligibility criteria included documented progression of disease; patients with bone lesions only ...
A number of recombinant plasmids coding for fusion proteins between human interferon-gamma (IFN-gamma) and human tumour necrosis factor alpha (TNF alpha) or beta (TNF beta) were constructed by using site-directed mutagenesis and ligation of the respective genes. In these proteins the whole IFN-gamma sequence of the molecule is linked at the N terminus via a short polypeptide linker to the TNF alpha sequence lacking two N-terminal amino acid residues or to the whole TNF beta sequence. A series of mutants with deletions in the interferon part of the fusion proteins were also produced. All the fusion genes obtained were efficiently expressed in Escherichia coli under the control of early promoters of bacteriophage T7. The recombinant fusion proteins were found to be unstable inside bacterial cells. Bacterial cell lysates expressing these fusion genes or their deletion mutants showed both biological activities in vitro: the antiviral activity of IFN-gamma and the cytotoxic activity of TNF.
The anti-tumor activity of recombinant human tumor necrosis factor (rHTNF) was examined against four newly induced murine sarcomas (MCA-101, -102, -105, and -106) and a murine adenocarcinoma (MCA-38) transplanted s.c. into C57BL/6 mice. The serum half-life after a single i.v. injection of rHTNF was determined to be 30 +/- 2 min. Tumor-bearing mice were more susceptible to the toxic side effects of rHTNF than were normal mice. Forty-eight percent (41/86) of tumor bearing animals that received 10 micrograms rHTNF died within 48 hr after treatment compared with no deaths in 28 normal animals receiving this dose. Treatment of mice bearing either the MCA-101, -102, -105, or -106 sarcoma or the MCA-38 adenocarcinoma with rHTNF resulted in a marked necrosis of the central portion of each tumor within 24 hr. Animals bearing the weakly immunogenic tumors MCA-105, -106, and -38 experienced a reduction in average tumor area of 47% +/- 5, 46% +/- 6, and 37% +/- 11, respectively, by 3 to 4 days after ...
Project Title: Extended cell-free protein expression system for amino acid labeling and structural biology studies at Miami Universitys Center for Bioinformatics and Functional Genomics (CBFG).. Project Lead: Carole Dabney-Smith. Email: [email protected] Phone: (513) 529-8091. Affiliation: CAS. Other Team Members: Andor Kiss, Gary A. Lorigan. Project Details: This project is a request for a temperature regulated, heating and cooling capable, mixing, dry incubator with accessories capable of handling tube with different volumes and a starter expression kit. This will enable undergraduate and graduate student users to produce microgram to milligram quantities of in vitro expressed protein in a semi-high throughput fashion to aid in the investigation of protein structure/function relationships of any protein. One consistent barrier that impedes the progress of, discovery of structure/function relationships has been the ability to reliably and quickly generate protein, e.g., with single amino ...
TY - JOUR. T1 - Recombinant human thrombopoietin in combination with granulocyte colony- stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy. AU - Somlo, George. AU - Sniecinski, Irena. AU - Ter Veer, Anna. AU - Longmate, Jeffrey. AU - Knutson, Gaylord. AU - Vuk-Pavlovic, Stanimir. AU - Bhatia, Ravi. AU - Chow, Warren. AU - Leong, Lucille. AU - Morgan, Robert. AU - Margolin, Kim. AU - Raschko, James. AU - Shibata, Stephen. AU - Tetef, Merry. AU - Yen, Yun. AU - Forman, Stephen. AU - Jones, Dennie. AU - Ashby, Mark. AU - Fyfe, Gwen. AU - Hellmann, Susan. AU - Doroshow, James H.. PY - 1999/5/1. Y1 - 1999/5/1. N2 - Lineage-specific growth factors mobilize peripheral blood progenitor cells (PBPC) and accelerate hematopoietic recovery after high-dose chemotherapy. Recombinant human thrombopoietin (rhTPO) may further increase the progenitor-cell content ...
This study has examined the effect of the cytokine interleukin 1 (IL-1) on metastasis formation by the human melanoma A375M in nude mice. We have found that human recombinant IL-1β (a single injection ,0.01 µg per mouse i.v. given before tumor cells) induced an augmentation of experimental lung metastases from the A375M tumor cells in nude mice. This effect was rapidly induced and reversible within 24 h after IL-1 injection. A similar effect was induced by human recombinant IL-1α and human recombinant tumor necrosis factor, but not by human recombinant interleukin 6. 5-[125I]Iodo-2′-deoxyuridine-radiolabeled A375M tumor cells injected i.v. remained at a higher level in the lungs of nude mice receiving IL-1 than in control mice. In addition, IL-1 injected 1 h, but not 24 h, after tumor cells enhanced lung colonization as well, thus suggesting an effect of IL-1 on the vascular transit of tumor cells. These findings may explain the observation of enhanced secondary localization of tumor cells ...
The human tumor necrosis factor alpha (TNF-alpha) gene is one of the earliest genes transcribed after the stimulation of a B cell through its antigen receptor or via the CD-40 pathway. In both cases, induction of TNF-alpha gene transcription can be blocked by the immunosuppressants cyclosporin A and FK506, which suggested a role for the NFAT family of proteins in the regulation of the gene in B cells. Furthermore, in T cells, two molecules of NFATp bind to the TNF-alpha promoter element kappa 3 in association with ATF-2 and Jun proteins bound to an immediately adjacent cyclic AMP response element (CRE) site. Here, using the murine B-cell lymphoma cell line A20, we show that the TNF-alpha gene is regulated in a cell-type-specific manner. In A20 B cells, the TNF-alpha gene is not regulated by NFATp bound to the kappa 3 element. Instead, ATF-2 and Jun proteins bind to the composite kappa 3/CRE site and NFATp binds to a newly identified second NFAT site centered at -76 nucleotides relative to the ...
The mortality rate at eight weeks was similar in the lenograstim and placebo groups (23 and 27 percent, respectively; P = 0.60), as was the incidence of severe infections. The median duration of neutropenia (absolute neutrophil count , or = 1000 per cubic millimeter) was shorter in the lenograstim group (21 days, as compared with 27 days in the placebo group; P , 0.001). Eight percent of the patients in both groups had regrowth of AML cells. The rate of complete remission was significantly higher in the lenograstim group (70 percent, as compared with 47 percent in the placebo group; P = 0.002). Overall survival, however, was similar in the two groups (P = 0.76). Conclusions: ...
Animal Model. Neonatal Wistar rats were randomly divided into three groups: 1) no-stroke control, 2) saline control, and 3) rhEPO treatment. The surgical procedure of whisker-barrel cortex ischemia in neonatal rats followed similar methods as described previously (Wei et al., 2006). In brief, postnatal day 7 (P7) pups were anesthetized by hypothermia. Hypothermia anesthesia was chosen because many of the drugs used to anesthetize adult animals provided inadequate anesthesia for neonates or were associated with problems such as excessively high mortality (Danneman and Mandrell, 1997). In this regard, hypothermia (immersion in ice) has been judged as a humane, safe, and effective anesthesia method for survival surgeries of neonatal rats (Danneman and Mandrell, 1997). The hypothermia procedure was kept the same for all pups in different experimental groups. Pups were placed in a noninvasive head-holder to allow for a 2.5- to 3.0-mm-diameter craniectomy through the right parietal skull. The ...
Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study; exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, Sjogrens syndrome, ...
Unconjugated Whole IgG Rabbit anti-CD3E Recombinant Monoclonal Antibody [BL-298-5D12] suitable for WB, IP, IHC, ICC, IHC-IF, F, mIF applications. Visit Bethyl.com for all your antibody needs.
What is the difference between Parental Type and Recombinant Type Chromosomes? Crossover not occurs in parental type chromosomes; in recombinant type
克拉玛尔专业提供Recombinant Human Interleukin-5高品质试剂,可查询Recombinant Human Interleukin-5价格,提供Recombinant Human Interleukin-5技术资料,Recombinant Human Interleukin-5定制合成和大包装,是专业生产各种高端试剂的制造商和供应商.联系电话4001650900
Active Recombinant human G-CSF protein is a HEK 293 Protein fragment 31 to 204 aa range, | 95% purity, | 1.000 Eu/µg endotoxin level and validated in FuncS, SDS-PAGE. The bio-activity was determined …
Buy our Recombinant Human G-CSF protein. Ab54137 is a protein fragment produced in Escherichia coli and has been validated in SDS-PAGE. Abcam provides free…
Recombinant protein production in mammalian cells is an important topic in biotechnology [1]. One of the critical steps in the production of recombinant proteins is the isolation of stable single cell clones expressing high levels of the protein of interest. Commonly, this is achieved by random genomic integration of a vector containing a promoter, a gene of interest and a selectable marker. Although this method is simple and straight forward, it lacks of reproducibility. Expression from such vectors is substantially influenced by the surrounding chromatin to the integration site and tends to be silenced over time. This makes the selection of suitable clones a tedious and time consuming procedure [1]. Several strategies have been developed to overcome the positional effects of the adjacent chromatin. For example, anti-repressor elements flanking the vectors [2] have been used or vectors have been integrated specifically into chromosomal loci with open chromatin [3]. Ideally, a vector for ...
etc. the cell physiology is affected. Cells are stressed, and this may severely affect growth, by-product accumulation, biomass yield and recombinant product yield. The stress caused by exposure to divergent microenvironments, genetic differences of individual cells, differing cell cycle stage and cell age, all contribute to make a population in a fermenter heterogeneous, resulting in cell-to-cell variation in physiological parameters of the microbial culture. Our study aims at investigating how population heterogeneity and recombinant protein production is affected by environmental gradients in bioreactors. For this purpose, a Saccharomyces cerevisiae strain, that functions as a protein production reporter, has been developed. A heterologous protein has been tagged with a fluorescent protein providing a way to measure the amount of heterologous protein produced by the cells on single cell level. Gradients are simulated in small bioreactors and the population heterogeneity can be visualised by ...
We have used transgenic mouse technology to establish immortalized hepatoma cell lines stably secreting heterologous proteins, such as human α1-antitrypsin and human factor IX. Hepatocyte-specific...
Protein titers, a key bioprocessing metric, depend both on the synthesis of protein and the degradation of protein. Secreted recombinant protein production in Saccharomyces cerevisiae is an attractive platform as minimal media can be used for cultivation, thus reducing fermentation costs and simplifying downstream purification, compared to other systems that require complex media. As such, engineering S. cerevisiae to improve titers has been then the subject of significant attention, but the majority of previous efforts have been focused on improving protein synthesis. Here, we characterize the protein uptake and degradation pathways of S. cerevisiae to better understand its impact on protein secretion titers. We do find that S. cerevisiae can consume significant (in the range of 1 g/L/day) quantities of whole proteins. Characterizing the physiological state and combining metabolomics and transcriptomics, we identify metabolic and regulatory markers that are consistent with uptake of whole ...
The following is a list of notable proteins that are generated from recombinant DNA, using biomolecular engineering, focusing on those that are used in human and veterinary medicine. In many cases, recombinant human proteins have replaced the original animal-derived version used in medicine. The prefix rh for recombinant human appears less and less in the literature. A much larger number of recombinant proteins is used in the research laboratory. These include both commercially available proteins (for example most of the enzymes used in the molecular biology laboratory), and those that are generated in the course specific research projects. Human growth hormone (rHGH): Humatrope from Lilly and Serostim from Serono replaced cadaver harvested human growth hormone human insulin (BHI): Humulin from Lilly and Novolin[disambiguation needed] from Novo Nordisk among others largely replaced bovine and porcine insulin for human therapy. Some prefer to continue using the animal-sourced preparations, as ...
Portland, Maine (PRWEB) June 18, 2014 -- Maine Biotechnology Services is announcing the addition of Bacterial Recombinant Protein Expression and Purification
Every kind of biological life process, from small to large, multiply, life and death, metabolism, is related to enzymes. If there is no catalysis of enzymes, the most basic food digestion in life and oxygen breathing can not be carried out. In fact, the various reactions occurring in the body are almost always carried out by the enzyme. It can be said that there is no enzyme, there is no life.. Here are three enzyme catalytic systems, which let us better understand the function and function of the enzyme from Creative Enzymes.. E. coli Enzyme Expression System. To date, a variety of prokaryotic and eukaryotic expression systems have been developed to produce recombinant proteins. Compared with other systems, Escherichia coli expression system has the advantages of clear genetic background, easy operation, large-scale fermentation culture, and is the most commonly used expression system at this stage. However, in the process of exogenous gene expression, there may be problems such as low ...
We have investigated the ability of recombinant TNF (mouse and human) to produce acute inflammatory lesions in an established experimental model of inflammation
Both exposure to oxygen and recombinant protein production are known to have adverse effects on microbial fermentation, including increased proteolytic and oxidative damage to the product. In an effort to characterize the effects of these stresses on the cell, DNA microarrays were used to monitor global gene expression of E. coli producing recombinant human αl-antitrypsin (α₁AT) during exposure to defined aeration conditions. Recombinant α₁AT has been shown to undergo oxygen-dependent degradation during production in E. coli, due in part to activation of the heat-shock response. The goal of this work is to better understand the effects of oxygen in order to improve this recombinant protein production process. In order to study the effects of oxygen extremes, global expression analysis was performed on α₁AT-producing cultures exposed to pure nitrogen, air, and pure oxygen. The most notable effects of oxygen exposure were those of superoxide. This reactive oxygen species is generated ...
Background Although most of antimicrobial peptides (AMPs), being relatively short, are produced by chemical synthesis, several AMPs have been produced using recombinant technology. However, AMPs could be cytotoxic to the producer cell, and if small they can be easily degraded. The objective of this study was to produce a multidomain antimicrobial protein based on recombinant protein nanoclusters to increase the yield, stability and effectivity. Results A single antimicrobial polypeptide JAMF1 that combines three functional domains based on human α-defensin-5, human XII-A secreted phospholipase A2 (sPLA2), and a gelsolin-based bacterial-binding domain along with two aggregation-seeding domains based on leucine zippers was successfully produced with no toxic effects for the producer cell and mainly in a nanocluster structure. Both, the nanocluster and solubilized format of the protein showed a clear antimicrobial effect against a broad spectrum of Gram-negative and Gram-positive bacteria, ...
Recombinant rabbit monoclonal antibody raised against EGFR. Original antibody is raised against recombinant protein corresponding to extracellular domain of mouse EGFR. (RAB00103) - Products - Abnova
Recombinant rabbit monoclonal antibody raised against full length human HSP90B1. Recombinant protein corresponding to full-length human HSP90B1. (RAB00648) - Products - Abnova
ABSTRACT: BACKGROUND: Recombinant protein production is a process of great industrial interest, with products that range from pharmaceuticals to bi...
Membrane proteins are some of the most interesting cellular proteins, serving as sensors and transducers of diverse signals, yet they also are the most…
Making Recombinant Proteins - posted in Protein Expression and Purification: My boss wants me to make a recombinant protein and this is something that I have never done before. The protein that I want to make is Recombinant Human Bone Morphogenetic Protein-7 and the product sheet of this compound where we first purchased the protein states that it is a 28.8 kDa homodimer, each subunit contains 116 amino acid residues (corresponding to amino acid residues 316 to 431 of the full-length...
The use of genetic and protein engineering techniques have led to a significant progress in animal production and it is starting to have a commercial impact in this field. Nowadays it is possible to design tailor-made sequences of enzymes, which in some cases combine specific properties of different enzymes in one molecule to obtain an optimal functional protein [181]. On the other hand, this technology allows the production of recombinant hormones through cost-effective processes using microbial cells as production hosts. In addition to this, novel strategies such as those based on passive immunization are gaining ground due to the broad range of possibilities that recombinant protein production offers. In this context, although important efforts have been done toward the minimization of recombinant protein production costs, currently, much remains still to be achieved. Cost effectiveness is particularly important in the context of animal production, where marginal returns are tight. Currently, ...
The present invention relates to a method of producing a target protein, which method comprises expressing said protein in a host cell which contains a nucleic acid molecule which encodes a chimeric